GlycoMimetics to Present at Upcoming Healthcare Investor Conferences
November 09 2017 - 9:15AM
Business Wire
GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Chief
Executive Officer Rachel King will provide a company overview at
two healthcare investor conferences next week, as follows:
STIFEL 2017 HEALTHCARE CONFERENCEWhen:
November 14, 2017 at 8:00 a.m. ETWhere: New York, NY, USA
JEFFERIES 2017 LONDON HEALTHCARE
CONFERENCEWhen: November 16, 2017 at 3:20 p.m. GMTWhere:
London, UK
To access the live webcast and subsequent archived recordings
for the presentation, please visit
the GlycoMimetics website
at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly-owned drug candidate, GMI-1271, an
E-selectin antagonist, is being evaluated in an ongoing Phase 1/2
clinical trial as a potential treatment for AML and in a Phase 1
clinical trial for the treatment of multiple myeloma. The U.S.
Food & Drug Administration recently granted GMI-1271
Breakthrough Therapy designation for the treatment of adult
acute myeloid leukemia (AML) patients with relapsed/refractory
disease. GlycoMimetics has also recently initiated a Phase 1
clinical trial with a third drug candidate, GMI-1359, a combined
CXCR4 and E-selectin antagonist. GlycoMimetics is located
in Rockville, Maryland, in the BioHealth Capital
Region. Learn more at www.glycomimetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171109005461/en/
GlycoMimeticsInvestors:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024